Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

December 2022 | 54 pages | ID: H113C4DA9F5CEN
Global Markets Direct

Abstracts

Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hyperinsulinemia - Overview
Hyperinsulinemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperinsulinemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperinsulinemia - Companies Involved in Therapeutics Development
AmideBio, LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Xeris Biopharma Holdings Inc
Zealand Pharma AS
Hyperinsulinemia - Drug Profiles
ABG-023 - Drug Profile
Product Description
Mechanism Of Action
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
CRN-04777 - Drug Profile
Product Description
Mechanism Of Action
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
glucagon - Drug Profile
Product Description
Mechanism Of Action
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
PB-722 - Drug Profile
Product Description
Mechanism Of Action
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
SNB-2401 - Drug Profile
Product Description
Mechanism Of Action
Hyperinsulinemia - Dormant Projects
Hyperinsulinemia - Discontinued Products
Hyperinsulinemia - Product Development Milestones
Featured News & Press Releases
Nov 28, 2022: Crinetics Pharmaceuticals provides update on CRN04777 Program
Oct 06, 2022: Innovation passport granted for CRN04777 for the treatment of congenital hyperinsulinism
Oct 04, 2022: AmideBio awarded SBIR phase IIb grant to support pre-clinical development of its long-acting stable glucagon analog for the treatment of hyperinsulinism
Sep 19, 2022: Zealand Pharma presents data from phase 3 trial of dasiglucagon in congenital hyperinsulinism at the 60th Annual ESPE Meeting
Sep 17, 2022: Rezolute announces presentation at the 60th Annual ESPE Meeting
Jun 13, 2022: Eiger BioPharmaceuticals announces new data supporting broader potential of avexitide in patients with post-bariatric hypoglycemia and hyperinsulinemic hypoglycemia after gastrointestinal surgeries
May 19, 2022: Zealand Pharma announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI)
May 01, 2022: Rezolute announces positive data from its phase 2b (RIZE) Study of RZ358 in patients with congenital hyperinsulinism
Apr 26, 2022: Rezolute announces RZ358 Phase 2b (RIZE Study) topline data to be unveiled at Pediatric Endocrine Society 2022 Annual Meeting
Mar 30, 2022: Crinetics Pharmaceuticals reports positive top-line results from CRN04777 phase 1 study multiple-ascending dose cohorts
Sep 22, 2021: Rezolute presents results from two-week natural history study in congenital hyperinsulinism patients on standard of care therapies at ESPE 2021
Sep 15, 2021: Crinetics Pharmaceuticals’ oral SST5 agonist CRN04777 demonstrated pharmacologic proof-of-concept with strong dose-dependent suppression of insulin secretion in phase 1 single ascending dose study
Sep 09, 2021: Rezolute announces initiation of dosing in the second cohort of its phase 2b trial of RZ358 for congenital hyperinsulinism
Feb 03, 2021: Crinetics Pharmaceuticals advances CRN04777 for congenital hyperinsulinism into phase 1 study
Jan 21, 2021: Hanmi Pharmaceutical’s innovative new drug HM15136 receives FDA phase 2 clinical trial approval
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperinsulinemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hyperinsulinemia - Pipeline by AmideBio, LLC, 2022
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, 2022
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, 2022
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Hyperinsulinemia - Pipeline by PegBio Co Ltd, 2022
Hyperinsulinemia - Pipeline by Rezolute Inc, 2022
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, 2022
Hyperinsulinemia - Pipeline by Xeris Biopharma Holdings Inc, 2022
Hyperinsulinemia - Pipeline by Zealand Pharma AS, 2022
Hyperinsulinemia - Dormant Projects, 2022
Hyperinsulinemia - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperinsulinemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022